Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803

Objective Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small cell lung cancer is needed. Methods A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 2013-07, Vol.146 (1), p.9-16
Hauptverfasser: Jaklitsch, Michael T., MD, Gu, Lin, MS, Demmy, Todd, MD, Harpole, David H., MD, D'Amico, Thomas A., MD, McKenna, Robert J., MD, Krasna, Mark J., MD, Kohman, Leslie J., MD, Swanson, Scott J., MD, DeCamp, Malcolm M., MD, Wang, Xiaofei, PhD, Barry, Susan, BS, Sugarbaker, David J., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 16
container_issue 1
container_start_page 9
container_title The Journal of thoracic and cardiovascular surgery
container_volume 146
creator Jaklitsch, Michael T., MD
Gu, Lin, MS
Demmy, Todd, MD
Harpole, David H., MD
D'Amico, Thomas A., MD
McKenna, Robert J., MD
Krasna, Mark J., MD
Kohman, Leslie J., MD
Swanson, Scott J., MD
DeCamp, Malcolm M., MD
Wang, Xiaofei, PhD
Barry, Susan, BS
Sugarbaker, David J., MD
description Objective Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small cell lung cancer is needed. Methods A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non–small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. Results Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. Conclusions Videothoracoscopy restaging was “feasible” in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.
doi_str_mv 10.1016/j.jtcvs.2012.12.069
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1369234452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0022522312016558</els_id><sourcerecordid>1369234452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-b44ce048cb27e32450afae76789059e9ffbf8eb575def651b0a3e6dc118125193</originalsourceid><addsrcrecordid>eNqFUkuO1DAQjRCI6Rk4ARLyclik8SfOBwmkYTQMLY0A8ZHYWY5TnnFIx8F2Wuodd-AqnIiTUKEHFmyQSvai3quqV6-y7BGja0ZZ-bRf98ns4ppTxtcYtGzuZCtGmyova_n5brailPNcci6OsuMYe0ppRVlzPzvioirrmhar7Me74OMEJrkdkOlGRyCbDUnB6YF4S6YAAeKS9iNJNz5o46PxkzNkC53TMbkRkYhJ-tqN10TbBIGM4HXXzzs9JmRB0NOeWB-w9OaMnL7hT8jox5_fvsetHgZiAJ9hRrbRo4HwjLyHOA8pLhOcn11dviQ4ZfLGD0Q0NRUPsntWDxEe3v4n2adXFx_PX-dXby83SMhNIZuUt0VhgBa1aXkFgheSaquhKqu6obKBxtrW1tDKSnZgS8laqgWUnWGsZlyyRpxkp4e6U_BfZ9Soti4u02oUOEfFRNlwURSSI1QcoAb3GQNYNQW31WGvGFWLXapXv-1Si10KA-1C1uPbBnOL-_zL-eMPAp4fAIAydw6CisYBLqlzAV1RnXf_afDiH74Z3OiMHr7AHmLv54D-oRIVkaA-LBezHAzDIqWUtfgFfJK_MQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1369234452</pqid></control><display><type>article</type><title>Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Jaklitsch, Michael T., MD ; Gu, Lin, MS ; Demmy, Todd, MD ; Harpole, David H., MD ; D'Amico, Thomas A., MD ; McKenna, Robert J., MD ; Krasna, Mark J., MD ; Kohman, Leslie J., MD ; Swanson, Scott J., MD ; DeCamp, Malcolm M., MD ; Wang, Xiaofei, PhD ; Barry, Susan, BS ; Sugarbaker, David J., MD</creator><creatorcontrib>Jaklitsch, Michael T., MD ; Gu, Lin, MS ; Demmy, Todd, MD ; Harpole, David H., MD ; D'Amico, Thomas A., MD ; McKenna, Robert J., MD ; Krasna, Mark J., MD ; Kohman, Leslie J., MD ; Swanson, Scott J., MD ; DeCamp, Malcolm M., MD ; Wang, Xiaofei, PhD ; Barry, Susan, BS ; Sugarbaker, David J., MD ; CALGB Thoracic Surgeons</creatorcontrib><description>Objective Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small cell lung cancer is needed. Methods A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non–small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. Results Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. Conclusions Videothoracoscopy restaging was “feasible” in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/j.jtcvs.2012.12.069</identifier><identifier>PMID: 23768804</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Adult ; Aged ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Carcinoma, Non-Small-Cell Lung - therapy ; Cardiothoracic Surgery ; Feasibility Studies ; Female ; Humans ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Lung Neoplasms - therapy ; Male ; Mediastinum ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Prospective Studies ; Thoracic Surgery, Video-Assisted ; Thoracoscopy - methods</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 2013-07, Vol.146 (1), p.9-16</ispartof><rights>The American Association for Thoracic Surgery</rights><rights>2013 The American Association for Thoracic Surgery</rights><rights>Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-b44ce048cb27e32450afae76789059e9ffbf8eb575def651b0a3e6dc118125193</citedby><cites>FETCH-LOGICAL-c459t-b44ce048cb27e32450afae76789059e9ffbf8eb575def651b0a3e6dc118125193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jtcvs.2012.12.069$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23768804$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaklitsch, Michael T., MD</creatorcontrib><creatorcontrib>Gu, Lin, MS</creatorcontrib><creatorcontrib>Demmy, Todd, MD</creatorcontrib><creatorcontrib>Harpole, David H., MD</creatorcontrib><creatorcontrib>D'Amico, Thomas A., MD</creatorcontrib><creatorcontrib>McKenna, Robert J., MD</creatorcontrib><creatorcontrib>Krasna, Mark J., MD</creatorcontrib><creatorcontrib>Kohman, Leslie J., MD</creatorcontrib><creatorcontrib>Swanson, Scott J., MD</creatorcontrib><creatorcontrib>DeCamp, Malcolm M., MD</creatorcontrib><creatorcontrib>Wang, Xiaofei, PhD</creatorcontrib><creatorcontrib>Barry, Susan, BS</creatorcontrib><creatorcontrib>Sugarbaker, David J., MD</creatorcontrib><creatorcontrib>CALGB Thoracic Surgeons</creatorcontrib><title>Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>Objective Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small cell lung cancer is needed. Methods A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non–small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. Results Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. Conclusions Videothoracoscopy restaging was “feasible” in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.</description><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Cardiothoracic Surgery</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Mediastinum</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Prospective Studies</subject><subject>Thoracic Surgery, Video-Assisted</subject><subject>Thoracoscopy - methods</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUkuO1DAQjRCI6Rk4ARLyclik8SfOBwmkYTQMLY0A8ZHYWY5TnnFIx8F2Wuodd-AqnIiTUKEHFmyQSvai3quqV6-y7BGja0ZZ-bRf98ns4ppTxtcYtGzuZCtGmyova_n5brailPNcci6OsuMYe0ppRVlzPzvioirrmhar7Me74OMEJrkdkOlGRyCbDUnB6YF4S6YAAeKS9iNJNz5o46PxkzNkC53TMbkRkYhJ-tqN10TbBIGM4HXXzzs9JmRB0NOeWB-w9OaMnL7hT8jox5_fvsetHgZiAJ9hRrbRo4HwjLyHOA8pLhOcn11dviQ4ZfLGD0Q0NRUPsntWDxEe3v4n2adXFx_PX-dXby83SMhNIZuUt0VhgBa1aXkFgheSaquhKqu6obKBxtrW1tDKSnZgS8laqgWUnWGsZlyyRpxkp4e6U_BfZ9Soti4u02oUOEfFRNlwURSSI1QcoAb3GQNYNQW31WGvGFWLXapXv-1Si10KA-1C1uPbBnOL-_zL-eMPAp4fAIAydw6CisYBLqlzAV1RnXf_afDiH74Z3OiMHr7AHmLv54D-oRIVkaA-LBezHAzDIqWUtfgFfJK_MQ</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Jaklitsch, Michael T., MD</creator><creator>Gu, Lin, MS</creator><creator>Demmy, Todd, MD</creator><creator>Harpole, David H., MD</creator><creator>D'Amico, Thomas A., MD</creator><creator>McKenna, Robert J., MD</creator><creator>Krasna, Mark J., MD</creator><creator>Kohman, Leslie J., MD</creator><creator>Swanson, Scott J., MD</creator><creator>DeCamp, Malcolm M., MD</creator><creator>Wang, Xiaofei, PhD</creator><creator>Barry, Susan, BS</creator><creator>Sugarbaker, David J., MD</creator><general>Mosby, Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803</title><author>Jaklitsch, Michael T., MD ; Gu, Lin, MS ; Demmy, Todd, MD ; Harpole, David H., MD ; D'Amico, Thomas A., MD ; McKenna, Robert J., MD ; Krasna, Mark J., MD ; Kohman, Leslie J., MD ; Swanson, Scott J., MD ; DeCamp, Malcolm M., MD ; Wang, Xiaofei, PhD ; Barry, Susan, BS ; Sugarbaker, David J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-b44ce048cb27e32450afae76789059e9ffbf8eb575def651b0a3e6dc118125193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Cardiothoracic Surgery</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Mediastinum</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Prospective Studies</topic><topic>Thoracic Surgery, Video-Assisted</topic><topic>Thoracoscopy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaklitsch, Michael T., MD</creatorcontrib><creatorcontrib>Gu, Lin, MS</creatorcontrib><creatorcontrib>Demmy, Todd, MD</creatorcontrib><creatorcontrib>Harpole, David H., MD</creatorcontrib><creatorcontrib>D'Amico, Thomas A., MD</creatorcontrib><creatorcontrib>McKenna, Robert J., MD</creatorcontrib><creatorcontrib>Krasna, Mark J., MD</creatorcontrib><creatorcontrib>Kohman, Leslie J., MD</creatorcontrib><creatorcontrib>Swanson, Scott J., MD</creatorcontrib><creatorcontrib>DeCamp, Malcolm M., MD</creatorcontrib><creatorcontrib>Wang, Xiaofei, PhD</creatorcontrib><creatorcontrib>Barry, Susan, BS</creatorcontrib><creatorcontrib>Sugarbaker, David J., MD</creatorcontrib><creatorcontrib>CALGB Thoracic Surgeons</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaklitsch, Michael T., MD</au><au>Gu, Lin, MS</au><au>Demmy, Todd, MD</au><au>Harpole, David H., MD</au><au>D'Amico, Thomas A., MD</au><au>McKenna, Robert J., MD</au><au>Krasna, Mark J., MD</au><au>Kohman, Leslie J., MD</au><au>Swanson, Scott J., MD</au><au>DeCamp, Malcolm M., MD</au><au>Wang, Xiaofei, PhD</au><au>Barry, Susan, BS</au><au>Sugarbaker, David J., MD</au><aucorp>CALGB Thoracic Surgeons</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>146</volume><issue>1</issue><spage>9</spage><epage>16</epage><pages>9-16</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><abstract>Objective Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small cell lung cancer is needed. Methods A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non–small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. Results Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. Conclusions Videothoracoscopy restaging was “feasible” in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>23768804</pmid><doi>10.1016/j.jtcvs.2012.12.069</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-5223
ispartof The Journal of thoracic and cardiovascular surgery, 2013-07, Vol.146 (1), p.9-16
issn 0022-5223
1097-685X
language eng
recordid cdi_proquest_miscellaneous_1369234452
source MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - surgery
Carcinoma, Non-Small-Cell Lung - therapy
Cardiothoracic Surgery
Feasibility Studies
Female
Humans
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Lung Neoplasms - therapy
Male
Mediastinum
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Prospective Studies
Thoracic Surgery, Video-Assisted
Thoracoscopy - methods
title Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A20%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20phase%20II%20trial%20of%20preresection%20thoracoscopic%20mediastinal%20restaging%20after%20neoadjuvant%20therapy%20for%20IIIA%20(N2)%20non%E2%80%93small%20cell%20lung%20cancer:%20Results%20of%20CALGB%20Protocol%2039803&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Jaklitsch,%20Michael%20T.,%20MD&rft.aucorp=CALGB%20Thoracic%20Surgeons&rft.date=2013-07-01&rft.volume=146&rft.issue=1&rft.spage=9&rft.epage=16&rft.pages=9-16&rft.issn=0022-5223&rft.eissn=1097-685X&rft_id=info:doi/10.1016/j.jtcvs.2012.12.069&rft_dat=%3Cproquest_cross%3E1369234452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1369234452&rft_id=info:pmid/23768804&rft_els_id=1_s2_0_S0022522312016558&rfr_iscdi=true